colorblindness impacts cancer detection

Colorblindness and bladder cancer might seem like an odd pairing, but a recent study reveals a troubling connection. Conducted by Ehsan Rahimy from Stanford University, the research analyzed electronic health records from over 275 million people. It compared 135 bladder cancer patients with color vision deficiency (CVD) to 135 matched patients without it. The findings? CVD patients face a whopping 52% higher 20-year mortality risk. In simpler terms, if you can’t see red, you might be in serious trouble.

At the ten-year mark post-diagnosis, just 50% of color-blind patients were still alive. That’s a stark contrast to the 75% survival rate of their non-CVD counterparts. The culprit? Delayed diagnosis. Bladder cancer often shows itself through painless hematuria—visible blood in urine. But guess what? CVD makes it harder to detect red colors, like blood. Imagine trying to spot ketchup on a gray plate. Not so easy, right?

A case study showed that 77% of color-blind participants correctly identified blood in urine photos, compared to 99% of those with normal vision. It’s like playing a game where the rules are rigged against you. Lack of adequate screening practices contributes to the higher mortality rates seen in color-blind patients. Bladder cancer survival rates decrease significantly for color-blind patients, emphasizing the need for better awareness in diagnosis.

With bladder cancer being a common issue—about 80,000 new cases each year—especially among older men, the overlap with CVD is alarming. Risk factors like age over 70, tobacco use, and industrial paint exposure don’t help either.

Yet, colorectal cancer didn’t show the same survival disparities. Why not? Blood in poop isn’t as tricky to detect as blood in urine.

You May Also Like

Scientists Catch Cancer’s Camouflage: How It Hides in Plain Sight

Cancer’s cunning tactics are more complex than you think. What if the secret to its survival lies in its deceptive camouflage? Read on to find out.

Cancer Survival Reaches 70%—So Why Are Warning Signs Growing?

Cancer survival rates have soared, yet alarming disparities persist. What factors threaten to undo this progress? The answers may surprise you.

Lunit Buys Washu Startup Prognosia—Will AI Redefine Breast Cancer Prediction?

Washington University startup’s overnight success could make traditional breast cancer prediction methods obsolete. AI might change everything we know about early detection.

Investigators Test Ivermectin’s Ability to Kill Cancer Cells

Can a common anti-parasitic drug hold the key to defeating cancer? The surprising research is just beginning to unfold.